MedTrace Logo

An Italian Experience on Grade 3b Follicular Lymphoma

NCT02927717 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-10-07

No results posted yet for this study

Summary

Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma.

Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.

Conditions

  • Grade 3b Follicular Lymphoma

Sponsors & Collaborators

  • A.O.U. Città della Salute e della Scienza

    lead OTHER

Principal Investigators

  • Barbara Botto, MD · A.O.U. Città della Salute e della Scienza

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-04-30
Completion
2017-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02927717 on ClinicalTrials.gov